TOVX stock icon

Theriva Biologics


Market Cap: 4.85M


About: Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Employees: 22

Funds holding %
of 6,702 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

202% more capital invested

Capital invested by funds: $452K [Q4 2023] → $1.37M (+$914K) [Q1 2024]

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

1.56% less ownership

Funds ownership: 6.17% [Q4 2023] → 4.61% (-1.56%) [Q1 2024]

4% less funds holding

Funds holding: 24 [Q4 2023] → 23 (-1) [Q1 2024]

20% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 5

Research analyst outlook

We haven’t received any recent analyst ratings for TOVX.

Financial journalist opinion